

Management of Urology

*Series Editors:* Sanchia S. Goonewardene · Raj Persad

Sanchia S. Goonewardene

Karen Ventii · Amit Bahl · Raj Persad

Hanif Motiwala · David Albala

# Management of Muscle Invasive Bladder Cancer

---

# Management of Urology

## Series Editors

Sanchia S. Goonewardene  
Southend University Hospital NHS Foundation Trust  
Southend, UK

Raj Persad  
North Bristol NHS Trust  
Bristol, UK

This series addresses the need for an increase in the quantity of literature focused upon the management in urology. Books within it will draw attention to the management of subtype specific urology. Therefore, it is of interest to a range of trainee and practicing physicians in a range of disciplines including urology, oncology, specialist nurse and general practitioners.

More information about this series at <http://www.springer.com/series/16626>

---

Sanchia S. Goonewardene • Karen Ventii  
Amit Bahl • Raj Persad • Hanif Motiwala  
David Albala

# Management of Muscle Invasive Bladder Cancer

Sanchia S. Goonewardene  
Southend University Hospital NHS  
Foundation Trust  
Southend  
UK

Amit Bahl  
North Bristol NHS Trust  
Bristol  
UK

Hanif Motiwala  
Southend University Hospital  
Westcliff-on-Sea  
UK

Karen Ventii  
Harvard University  
Boston, MA  
USA

Raj Persad  
North Bristol NHS Trust  
Bristol  
UK

David Albala  
Fayetteville, NY  
USA

ISSN 2730-6372

Management of Urology

ISBN 978-3-030-57914-2

<https://doi.org/10.1007/978-3-030-57915-9>

ISSN 2730-6380 (electronic)

ISBN 978-3-030-57915-9 (eBook)

© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2021

This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG  
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

---

## Preface

Welcome to Management of Muscle Invasive Bladder Cancer (NMIBC). The concept of this book first came to me as a young trainee, whilst assisting with cystectomies. I had often read papers, but very rarely understood controversies in management of muscle invasive bladder cancer.

Bladder cancer has considerable impact on patients. It presents aggressively, very often, already having advanced into muscle. The patient pathway is very often prolonged and, due to the nature of disease, has poor outcomes.

Bladder cancer is often considered the ‘Cinderella’ of all the cancers—underfunded for research. The aim of this book is to use the knowledge to further develop your practice and improve patient care. It has been a pleasure to put this together for you.

Southend, UK

Sanchia S. Goonewardene

---

## Acknowledgements

For my family and friends—always supporting me in what I do.

For all the superheroes in my life—you are truly inspirational.

For my team at Springer Nature, for always giving me a chance to get published.

For Dr. Ventii, a true friend and colleague.

For Prof Persad—my mentor for the past 7 years, thank you.

For Prof Motiwala—former TPD and Chief Examiner, FRCS Urol, a visionary in the urology field.

For Prof Albala—My Editor In Chief, friend and mentor—generally awesome.

For my TPD, Ms Georgina Wilson, for always supporting me and my academic endeavours.

---

# Contents

## Part I Introduction

<b>1 Introduction to Muscle Invasive Bladder Cancer</b> . . . . .	3
References. . . . .	4

## Part II Epidemiology and the Molecular Basis of Bladder Cancer

<b>2 Epidemiology and Risk Factors in Muscle Invasive Bladder Cancer</b> . . . . .	7
2.1 Research Methods . . . . .	7
2.2 Flavonoids and Bladder Cancer Risk. . . . .	9
2.3 Metabolic Factors and Risk of Bladder Cancer. . . . .	9
2.4 Smoking Cessation and Bladder Cancer Risk . . . . .	9
2.5 Occupational Exposure in Muscle Invasive Bladder Cancer. . . . .	10
2.6 Androgen Suppression Therapy and Risk of Muscle Invasive Bladder Cancer . . . . .	11
2.7 Reviews Associated with Epidemiology and Risk Factors in Bladder Cancer . . . . .	11
References. . . . .	11
<b>3 Epidemiology, Risk Factors and Occupational Hazards.</b> . . . .	13
3.1 Systematic Review Results on Bladder Cancer Epidemiology, Occupational Hazards and Risk Factors . . . . .	15
3.1.1 Bladder Cancer Survival . . . . .	15
3.1.2 Carcinogenic Agents: Population Studies . . . . .	15
3.1.3 Populations Studies with Women . . . . .	15
3.1.4 Population Studies with Men. . . . .	16
3.1.5 Arylamines. . . . .	16
3.1.6 Anilene Dyes . . . . .	17
3.1.7 Arsenic . . . . .	17
3.1.8 Textile Industry . . . . .	17
3.1.9 Metalworking Fluids Exposure . . . . .	18
3.1.10 Smoking and Bladder Cancer . . . . .	18
3.1.11 Impact of Occupational Risk Factors on Prognosis of Recurrent Bladder Cancer . . . . .	19



3.1.12 Results from the Literature and Other Reviews on Bladder Cancer Epidemiology, Risk Factors, Occupational Exposure . . . . .	19
References. . . . .	20
<b>4 The Molecular Basis of Muscle Invasive Bladder Cancer. . . . .</b>	<b>23</b>
4.1 Research Methods . . . . .	23
4.2 Systematic Review Results . . . . .	25
4.2.1 The Molecular Basis of Bladder Cancer: Precision Diagnostics and Treatment. . . . .	25
4.2.2 PIK3CA Mutations in Muscle Invasive Bladder Cancer . . . .	25
4.2.3 Epidermal Growth Factor in Muscle Invasive Bladder Cancer . . . . .	25
4.2.4 P53, pRB and RAS in Muscle Invasive Bladder Cancer . . . .	26
4.2.5 Transcriptome Profiling in Muscle Invasive Bladder Cancer. . . . .	26
4.2.6 Methylation Status in Bladder Cancer . . . . .	26
4.2.7 The Cancer Genome Project and the Molecular Basis of Bladder Cancer . . . . .	26
References. . . . .	27
<b>Part III Management of Histological Variants</b>	
<b>5 Histological Variants in MIBC: Squamous Cell and Squamous Differentiation. . . . .</b>	<b>31</b>
5.1 Risk Factors . . . . .	31
5.2 Survival Outcomes. . . . .	32
5.3 Squamous Cell and Evidence of Metastatic Disease. . . . .	32
References. . . . .	33
<b>6 Histological Variants in Muscle Invasive Bladder Cancer: Adenocarcinoma . . . . .</b>	<b>35</b>
6.1 Survival Outcomes in Bladder Adenocarcinoma: Radical Surgery vs. Resection. . . . .	35
6.2 CEA and CA 19-9 in Diagnostics in Muscle Invasive Adenocarcinoma of the Bladder . . . . .	36
6.3 Muscle Invasive Adenocarcinoma of the Bladder Mimicking a Ureteroceles . . . . .	37
6.4 Partial Cystectomy and Radiotherapy in Adenocarcinoma of the Bladder. . . . .	37
6.5 Neoadjuvant Chemotherapy in Bladder Adenocarcinoma. . . . .	37
6.6 Adjuvant Therapy in Adenocarcinoma of the Bladder . . . . .	38
6.7 Novel Chemotherapeutic Agents for Metastatic Adenocarcinoma of the Bladder . . . . .	38
6.8 Systematic Reviews Related: Lymphadenectomy in Adenocarcinoma of the Bladder . . . . .	38
References. . . . .	39

<b>7</b>	<b>Histological Variants in Muscle Invasive Bladder Cancer:</b>	
	<b>Sarcomatoid Cancer</b> . . . . .	41
7.1	Causes of Sarcomatoid Bladder Cancer. . . . .	41
7.2	Diagnostics in Sarcomatoid Bladder Cancer . . . . .	42
7.3	Clinicopathological and Immunohistochemical Diagnosis of Sarcomatoid Bladder Cancer . . . . .	42
7.4	Survival Outcomes with Radical Cystectomy and Sarcomatoid Carcinoma . . . . .	43
7.5	Adjuvant Chemotherapy in Sarcomatoid Bladder Cancer. . . . .	43
	References. . . . .	44
<b>8</b>	<b>MIBC Carcinosarcoma.</b> . . . .	45
8.1	The Genetic Basis of Carcinosarcoma. . . . .	45
8.2	Histopathology of Carcinosarcoma . . . . .	46
8.3	Clinical Presentation of Carcinosarcoma. . . . .	48
8.4	Survival Outcomes. . . . .	48
8.5	Surgical Treatment for Carcinosarcoma . . . . .	49
8.6	Adjuvant Therapy in Carcinosarcoma . . . . .	49
8.7	Neoadjuvant Chemotherapy in Carcinosarcoma . . . . .	50
	References. . . . .	51
<b>9</b>	<b>Muscle Invasive Bladder Cancer: Small Cell</b> . . . . .	53
9.1	Neuroendocrine Markers in Small Cell Bladder Cancer . . . . .	53
9.2	Cytological and Immunological Analyses in Small Cell Bladder Carcinoma. . . . .	53
9.3	Survival Outcomes. . . . .	54
9.4	Prognostic Factors in Diagnosis of Small Cell Bladder Cancer . . . .	54
9.5	Clinical Presentation of Small Cell Bladder Cancer . . . . .	55
9.6	Surgical Outcomes. . . . .	56
9.7	Neoadjuvant Chemotherapy in Small Cell Bladder Cancer. . . . .	57
9.8	Radiotherapy in Small Cell Cancer of the Bladder . . . . .	58
9.9	Adjuvant Therapy in Small Cell Cancer of the Bladder . . . . .	58
9.10	Chemotherapy and Radiotherapy in Metastatic Small Cell Carcinoma of the Bladder . . . . .	59
	References. . . . .	60
<b>10</b>	<b>MIBC Plasmacytoid Bladder Cancer</b> . . . . .	63
10.1	Clinical Presentation of Plasmacytoid Bladder Cancer . . . . .	63
10.2	Immunohistochemical Diagnosis in Plasmacytoid Cancer . . . . .	63
10.3	Survival Outcomes. . . . .	64
10.4	Surgical Outcomes in Plasmacytoid Bladder Cancer . . . . .	65
10.5	Patterns of Metastases: Plasmacytoid Bladder carcinoma. . . . .	66
10.6	Neoadjuvant Chemotherapy in Plasmacytoid Bladder Cancer . . . .	66
10.7	Recurrence in Plasmacytoid Bladder Cancer. . . . .	67
	References. . . . .	68

<b>11 MIBC and Micropapillary Bladder Cancer</b> . . . . .	71
11.1 Histopathology of Micropapillary Bladder Carcinoma . . . . .	71
11.2 Clinical Presentation of Micropapillary Bladder Cancer . . . . .	72
11.3 Clinical Risk Stratification in Micropapillary Bladder Cancer . . . . .	73
11.4 Survival Outcomes in Micropapillary Bladder Cancer . . . . .	73
11.5 Neoadjuvant Chemotherapy in Micropapillary Bladder Cancer . . . . .	74
11.6 Trimodal Therapy in Micropapillary Bladder Cancer . . . . .	74
11.7 Surgical Outcomes in Micropapillary Bladder Cancer . . . . .	74
11.8 Adjuvant Therapy in Micropapillary Bladder Cancer . . . . .	76
References . . . . .	76

## **Part IV Assessment and Diagnosis in MIBC**

<b>12 MIBC Bladder Cancer Assessment and Diagnosis</b> . . . . .	81
12.1 Clinical Presentation of Bladder Cancer . . . . .	81
12.2 Diagnosis and Assessment in Bladder Cancer . . . . .	82
12.3 The Role of Haematuria Clinics in Bladder Cancer . . . . .	83
12.4 Bladder Cancer Screening . . . . .	84
12.5 Biomarkers in Bladder Cancer Diagnostics . . . . .	84
12.6 Guidelines and Diagnostics in Bladder Cancer . . . . .	85
12.7 Diagnostic Imaging in Bladder Cancer . . . . .	85
12.8 Novel Methods for Diagnosis of Bladder Cancer . . . . .	86
12.9 Gender Discrepancies in Bladder Cancer Diagnostics . . . . .	87
References . . . . .	88
<b>13 Bladder Cancer Screening</b> . . . . .	91
13.1 Systematic Review Results . . . . .	92
13.1.1 Urinary Metabolomes in Bladder Cancer Screening . . . . .	92
13.1.2 CellDetect in Bladder Cancer Screening . . . . .	93
13.1.3 Blue Light Flexible Cystoscopy . . . . .	93
13.1.4 Bladder Epicheck in Bladder Cancer Screening . . . . .	97
13.1.5 Urinary miRNA-96 in Bladder Cancer Diagnosis . . . . .	97
13.1.6 Urinary Cytology in Bladder Cancer Screening . . . . .	97
13.1.7 Porphyrins as Urinary Biomarkers . . . . .	98
13.1.8 Quantitative mRNA Determination in Bladder Cancer Screening . . . . .	98
13.1.9 Biomarkers in Bladder Cancer Screening . . . . .	98
13.1.10 Cytokeratin 20 and IGF2 in Bladder Cancer Screening . . . . .	99
13.1.11 Angiogenin and Clusterin in Urinary Cytology in Bladder Cancer Screening . . . . .	99
13.1.12 Methylation and Line 1 in Bladder Cancer Screening . . . . .	99
13.1.13 Metabolomic Urinary Profiles in Bladder Cancer Screening . . . . .	100
13.1.14 Mitochondrial DNA in Bladder Cancer Screening . . . . .	100

13.1.15	Tyr-Phosphorylated Proteins in Bladder Cancer Screening . . . . .	100
13.1.16	GC-Globulin in Bladder Cancer Screening . . . . .	101
13.1.17	Methylation Status with p16 and p14 in Bladder Cancer Screening . . . . .	101
13.1.18	Urine Tumour Associated Trypsin Inhibitor. . . . .	101
13.1.19	mRNA in Bladder Cancer Screening . . . . .	102
13.1.20	Urinary Basic Fetoprotein and BTA Test in Urinary Cytology . . . . .	102
13.1.21	BTA Stat Test vs. NMP 22 vs. Urine Cytology . . . . .	102
13.1.22	NMP 22 as a Screening Test in Bladder Cancer. . . . .	103
13.1.23	Urinary Fibrin as a Screening Test for Bladder Cancer . . . . .	103
13.1.24	DNA Image Cytometry in Bladder Cancer Screening . . . . .	104
13.1.25	Matrix Metalloproteinases in Bladder Cancer Screening. . . . .	104
13.1.26	Microsatellite Markers in Bladder Cancer Screening. . . . .	104
13.1.27	Conclusion . . . . .	105
	References. . . . .	105
<b>14</b>	<b>A Systematic Review on Blue Light Cystoscopy in Bladder Cancer Diagnostics . . . . .</b>	<b>109</b>
14.1	Systematic Review Methods . . . . .	109
14.2	Systematic Review Results . . . . .	110
14.2.1	Blue Light vs. White Light Cystoscopy . . . . .	110
14.2.2	Efficacy and Safety of Blue Light vs. White Light in Bladder Cancer Diagnostics . . . . .	111
14.2.3	Blue Light Cystoscopy and Early Detection of Bladder Cancer. . . . .	112
14.2.4	Blue Light Cystoscopy and Malignant vs. Benign Lesions . . . . .	113
14.2.5	Role of Blue Light Cystoscopy in Detection of CIS . . . . .	114
14.2.6	Blue Light Cystoscopy in Atypical Bladder Cancer Diagnosis . . . . .	114
14.2.7	Role of Blue Light Cystoscopy in Positive Cytology. . . . .	114
14.2.8	Blue Light Cystoscopy and Role in Bladder Cancer Surveillance . . . . .	115
14.2.9	Blue Light Cystoscopy in Detection of Recurrence. . . . .	115
14.2.10	Blue Light Cystoscopy in High Risk Patients . . . . .	116
14.2.11	Blue Light Cystoscopy in Progression of Bladder Cancer. . . . .	116
14.2.12	Accuracy of Blue vs. White Light Cystoscopy . . . . .	116
14.2.13	Reviews Related to Systematic Review . . . . .	118
14.2.14	Grey Literature Related to Systematic Review. . . . .	118
14.2.15	Conclusions . . . . .	118
	References. . . . .	118

<b>15</b>	<b>Muscle Invasive Bladder Cancer and the Staging Conundrum: Which Imaging Modality Is Best?</b>	121
15.1	MRI in Bladder Cancer	121
15.2	PET Imaging in Bladder Cancer	123
	References.	125
<b>16</b>	<b>A Systematic Review on the Staging Conundrum in Bladder Cancer</b>	127
16.1	Systematic Review Results	128
16.1.1	Variation in Imaging for Bladder Cancer Staging	128
16.1.2	MRI in Detection of NMIBC vs. MIBC.	129
16.1.3	MRI in Low Grade vs. High Grade Bladder Cancer	129
16.1.4	Sensitivity and Specificity of MRI vs. CT Urogram	130
16.1.5	The Role of High Resolution Ultrasound in Bladder Cancer Staging	130
16.1.6	Staging and VIRADS	130
16.1.7	The Role of FDG PET in Bladder Cancer Staging.	131
16.1.8	Reviews Related to Systematic Review	131
16.1.9	Grey Literature Related to Systematic Review.	132
16.1.10	Systematic Review Conclusion	132
	References.	132
<b>17</b>	<b>Current State of Investigations and Limitations in Muscle Invasive Bladder Cancer</b>	135
17.1	MIBC: Is Upper Tract Imaging Required?	135
17.2	MIBC: Is There a Role for Urine Cytology in Haematuria Investigations?	135
17.3	Is Cystoscopy Required for Investigation of Microscopic Haematuria?	136
17.4	Role of Biomarkers as a Replacement for Haematuria Investigations	136
	References.	137
<b>18</b>	<b>Bladder Cancer Surveillance</b>	139
18.1	Research Methods	139
18.2	Systematic Review Results	141
18.2.1	Urinary Metabolites in Bladder Cancer Surveillance.	141
18.2.2	CellDetect in Bladder Cancer Surveillance	141
18.2.3	NMP 22 in Bladder Cancer Surveillance	142
18.2.4	5-Aminolevulinic Acid-Induced Fluorescence Endoscopy in Bladder Cancer Surveillance	142
18.2.5	The BTA Stat Test in Bladder Cancer Surveillance	143
18.2.6	Bladder EpiCheck in Bladder Cancer Surveillance	143
18.2.7	Microsatellite Analysis in Bladder Cancer Surveillance	143
18.2.8	Urinary Cytology, BTA Trak and Cytokeratin's 8 and 18	144
18.2.9	Urotel in Bladder Cancer Surveillance.	144
	References.	144

<b>19</b>	<b>Risk Stratification in Bladder Cancer</b>	147
19.1	Accuracy of EORTC Risk Stratification	147
19.2	EORTC Risk Stratification for MIBC Post Radical Cystectomy	147
19.3	EORTC/CUETO Risk Stratification in Second TURBT	148
19.4	Accuracy of EORTC and CUETO Scoring Systems	148
19.5	EORTC vs. EAU Risk Stratification	149
19.6	Assessment of BCG Therapy Using the CUETO Risk Stratification Model	150
19.7	AUA/SUO Guidelines in Bladder Cancer	150
19.8	EORTC Classification vs. AUA Guidelines for Bladder Cancer	150
	References	151
<b>20</b>	<b>Risk Prediction and Nomograms in Bladder Cancer</b>	153
20.1	Systematic Review Results	155
20.1.1	Molecular Markers in Bladder Cancer Risk	155
20.1.2	Preoperative Factors Predicting Risk	155
20.1.3	Prediction of Lymph Node Metastasis	155
20.1.4	Nomogram to Predict Survival in Bladder Cancer	156
20.1.5	Prediction of Recurrence Risk	157
20.1.6	Postoperative Factors Affecting Survival	158
20.1.7	Recurrence After Radical Cystectomy	158
	References	159
<b>21</b>	<b>Preventative Measures for Those with High Risk MIBC</b>	161
21.1	Mediterranean Diet and Bladder Cancer Risk	161
21.2	Risk Factors in Bladder Cancer: Preventative Measures	161
21.3	Preventative Measures in Bladder Cancer: Impact of Vitamin A	162
21.4	Prevention of Bladder Cancer: Fluid Intake	162
21.5	Mitomycin and BCG in Bladder Cancer Prevention	162
21.6	Preventative Measures and Urethral Recurrence	163
21.7	BCG in Intermediate and High-Risk Disease	163
	References	163
<b>22</b>	<b>Bladder Cancer Risk Post Pelvic Irradiation</b>	165
22.1	Radiation Induced Bladder Cancer Post Cervical Cancer	165
22.2	Clinical Presentation of Bladder Cancer Post-pelvic Irradiation	165
22.3	Survival Outcomes in Bladder Cancer Post Pelvic Irradiation	166
22.4	Prior Irradiation for Prostate Cancer and Risk of Bladder Cancer	166
22.5	Management of Pelvic Irradiation Induced Bladder Cancer	166
	References	167

## Part V Management of MIBC

<b>23</b>	<b>A Systematic Review on Bladder Preservation Strategies and MIBC</b>	171
23.1	Research Methods	171
23.2	Systematic Review Results	173

23.2.1	Tetramodal Bladder Preservation Therapy . . . . .	173
23.2.2	Radical Cystectomy vs. Bladder Preservation in the Elderly . . . . .	173
23.2.3	Bladder Perseveration with Brachytherapy and External Beam Radiotherapy . . . . .	173
23.2.4	Survival Outcomes in Bladder Preservation Therapy for MIBC . . . . .	174
23.2.5	Patterns of Bladder Preservation Therapy . . . . .	174
23.2.6	Bladder Preservation Rate . . . . .	174
23.2.7	Paclitaxel, Trasuzumab with Irradiation After Transurethral Surgery . . . . .	175
23.2.8	Second TURBT in Bladder Preservation for MIBC. . . . .	175
23.2.9	Trimodal Chemotherapy with Cisplatin in Bladder Preservation . . . . .	175
23.2.10	Grey Matter Relating to Systematic Review . . . . .	176
	References. . . . .	176
<b>24</b>	<b>Partial Cystectomy . . . . .</b>	<b>179</b>
24.1	Predictive Factors in Partial Cystectomy . . . . .	179
24.2	Partial Cystectomy Rate. . . . .	179
24.3	Molecular Markers Allow Prediction of Survival in Bladder Preservation Strategies . . . . .	180
24.4	Oncological Outcomes in Partial Cystectomy . . . . .	180
	References. . . . .	181
<b>25</b>	<b>Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer . . . . .</b>	<b>183</b>
25.1	Health Related Quality of Life in the Elderly with Radical Cystectomies. . . . .	184
25.2	Bladder Preservation Therapy in the Elderly . . . . .	185
25.3	Radiotherapy in Elderly Patients with MIBC . . . . .	185
25.4	Grey Literature. . . . .	186
	References. . . . .	186
<b>26</b>	<b>Muscle Invasive Bladder Cancer and Neoadjuvant Chemotherapy . . . . .</b>	<b>189</b>
26.1	The Rationale for Neoadjuvant Chemotherapy . . . . .	189
26.2	Neoadjuvant Chemotherapy: Clinical Effectiveness . . . . .	190
26.3	Meta-Analyses for Neoadjuvant Chemotherapy . . . . .	191
26.4	Disadvantages of Neoadjuvant Chemotherapy . . . . .	191
26.5	Targeted Therapies and Bladder Preservation . . . . .	192
26.6	Evaluation of 'QUALYs' . . . . .	192
26.7	Benefits vs. Risks of Neoadjuvant Chemotherapy. . . . .	192
26.8	Controversies in Clinical Effectiveness of Neoadjuvant Chemotherapy . . . . .	193
	References. . . . .	194

<b>27</b>	<b>Trimodal Therapy in Bladder Cancer.</b>	197
	References.	199
<b>28</b>	<b>Trimodal Therapy: A Systematic Review—Is It Really Better than Radical Therapy?</b>	201
28.1	Trimodal Chemotherapy	202
28.2	Efficacy of 5FU as Part of Trimodal Therapy	203
28.3	Outcomes from Trimodal Therapy for MIBC	203
28.4	Trimodal Therapy in the Elderly	206
28.5	Trimodal Therapy and Radical Cystectomy	206
28.6	Proton Beam Therapy in Trimodal Therapy	207
28.7	Reviews Related to Trimodal Therapy for MIBC	207
	References.	209

## **Part VI Radical Cystectomy**

<b>29</b>	<b>Radical Cystectomy Outcomes</b>	213
	References.	214
<b>30</b>	<b>Laparoscopic vs. Open vs. Robotic Cystectomy.</b>	217
	References.	219
<b>31</b>	<b>A Systematic Review on Radical Cystectomy:</b>	
	<b>Laparoscopic vs. Open vs. Robotic</b>	221
31.1	Research Methods	221
31.2	Complication Rate Robotic vs. Open Cystectomy	223
31.3	Laparoscopic vs. Open Radical Cystectomy with Prior Abdominal Surgery	224
31.4	Laparoscopic vs. Open Cystectomy Outcomes	225
31.5	Robotic Cystectomy vs. Laparoscopic Cystectomy Outcomes	225
31.6	Recurrence After Open and Robotic Radical Cystectomy.	225
31.7	Robotic vs. Laparoscopic Radical Cystectomy in Elderly Patients	226
31.8	Robotic vs. Laparoscopic High Extended Pelvic Lymph Node Dissection.	226
31.9	Open vs. Laparoscopic vs. Robotic Cystectomy	226
	References.	227
<b>32</b>	<b>Prostate Sparing Cystectomy: A Systematic Review</b>	229
32.1	Research Methods	229
32.2	Systematic Review: Results	231
32.2.1	A Modification of Technique: Prostate Sparing Cystectomy	231
32.2.2	Seminal Sparing Cystectomy	231
32.2.3	Oncological Outcomes of Prostate Sparing Cystectomy	232
32.2.4	Risk of Prostate/Urothelial Cancer in Prostate Sparing Cystectomy	233



32.2.5	Functional Outcomes Post Prostate Sparing Cystectomy .	234
32.2.6	Erectile Function after Prostate Sparing Cystectomy. ....	235
32.2.7	Post-operative Complications After Prostate Sparing Cystectomy. ....	236
32.2.8	Grey Literature Relating to Systematic Review. ....	237
	References. ....	237
<b>33</b>	<b>A Systematic Review on Nerve Sparing Cystoprostatectomy. ....</b>	<b>241</b>
33.1	Research Methods .	241
33.2	Outcomes of Nerve-Sparing in Radical Cystectomy. ....	243
33.3	Post-operative Complications in Nerve Sparing Prostatectomy ...	243
33.4	Radical Cystectomy and Nerve Sparing in Women. ....	244
33.5	Nerve Sparing in Either Gender. ....	244
33.6	Nerve Sparing Radical Cystectomy and Impact on Continence ...	244
33.7	Nerve Sparing Cystectomy and Impact on Orthotopic Neobladder. ....	245
33.8	Prostate Sparing vs. Nerve Sparing Cystectomy. ....	245
33.9	Outcomes in Nerve Sparing Cystectomy. ....	246
33.10	Penile Rehabilitation in Cystoprostatectomy. ....	246
33.11	High Risk Bladder Cancer and Nerve Sparing Radical Cystectomy .	247
	References. ....	247
<b>34</b>	<b>Robotic Radical Cystectomy and Lymph Node Dissection: What Are the New Ways Forward? .</b>	<b>249</b>
	References. ....	250
<b>35</b>	<b>A Systematic Review on RARC and LND .</b>	<b>253</b>
35.1	Research Methods .	253
35.2	Robotic RARC and LND. ....	255
35.3	Post-operative Complications from LND .	255
35.4	Extended Pelvic Lymphadenopathy in RARC. ....	255
35.5	Standard Lymphadenectomy in RARC .	256
35.6	Robotic Lymphadenectomy with the Da Vinci S. ....	256
35.7	Robotic vs. Open Lymphadenectomy .	257
35.8	Robotic vs. Laparoscopic Lymphadenectomy for Radical Cystectomy .	258
35.9	Grey Literature Relating to Review .	258
	References. ....	258
<b>36</b>	<b>Robotic Cystectomy and Sentinel Node Mapping .</b>	<b>261</b>
	References. ....	262
<b>37</b>	<b>MIBC and Radical Cystectomy in the Elderly: A Systematic Review .</b>	<b>263</b>
37.1	Research Methods .	263
37.2	Systematic Review Results .	265

37.2.1	Prognostic Factors in Elderly Patients . . . . .	265
37.2.2	Mortality Rate in Elderly undergoing Cystectomy. . . . .	265
37.2.3	Type of Reconstruction in the Elderly . . . . .	267
37.2.4	Open Radical Cystectomy . . . . .	268
37.2.5	Laparoscopic Radical Series in Elderly . . . . .	268
37.2.6	National Trends in Cystectomy Figures for the Elderly . . . . .	268
37.2.7	Robotic vs. Open Radical Cystectomy in Elderly . . . . .	269
37.2.8	Extraperitoneal vs. Transperitoneal Laparoscopic Approaches. . . . .	269
37.2.9	Younger vs. Older Patients for Radical Cystectomy . . . . .	269
37.2.10	Risks and Benefits of Pelvic Lymphadenectomy in the Elderly . . . . .	270
37.2.11	Outcomes in Elderly Patients . . . . .	270
37.2.12	Pathology of Elderly Patients Undergoing Radical Cystectomy. . . . .	271
37.2.13	Post-operative Outcomes in Younger and Older Patients . . . . .	271
37.2.14	Survival Benefit Younger vs. Older Patients: Radical Cystectomy . . . . .	272
	References. . . . .	273
<b>38</b>	<b>Female Outcomes in Bladder Cancer . . . . .</b>	<b>275</b>
38.1	Research Methods . . . . .	275
38.2	Prognostic Factors in Female Bladder Cancer. . . . .	277
38.3	Postoperative Complications in Female Gender for Cystectomy . . . . .	278
38.4	Survival Outcomes in Female Bladder Cancer . . . . .	278
38.5	Urethral Sparing Cystectomy. . . . .	280
38.6	Survival Outcomes in T4 Bladder Cancer in Females. . . . .	280
38.7	Health Related Quality of Life in Female Patients Post Radical Cystectomy . . . . .	281
38.8	Urethral Recurrence in Female Bladder Cancer . . . . .	281
38.9	Female Sexual Dysfunction After Radical Cystectomy and Neobladder Construction . . . . .	282
38.10	Reviews Related to the Systematic Review. . . . .	282
	References. . . . .	283
 <b>Part VII Radical Radiotherapy</b>		
<b>39</b>	<b>MIBC Radical Radiotherapy . . . . .</b>	<b>287</b>
39.1	Research Methods . . . . .	287
39.2	Overall Survival for Radical Radiotherapy . . . . .	289
39.3	Chemoradiation vs. Radical Cystectomy for MIBC . . . . .	289
39.4	Trimodal Therapy vs. Cystectomy. . . . .	289
39.5	Radiochemotherapy vs. Radical Cystectomy . . . . .	290

39.6	Radiochemotherapy in the Elderly.....	291
39.7	GU Toxicity from Radical Radiotherapy.....	292
39.8	Grey Matter .....	292
	References.....	293
<b>40</b>	<b>The Robotic Approach to Redo Surgery.....</b>	<b>295</b>
	References.....	296
<b>41</b>	<b>Secondary Pelvic Malignancies and Bladder Cancer .....</b>	<b>297</b>
	References.....	298
<b>42</b>	<b>Robotic Radical Cystectomy: Technical Tips and Tricks .....</b>	<b>299</b>
	References.....	301
<b>43</b>	<b>A Focus on Robotic Intracorporeal Neobladder Formation.....</b>	<b>303</b>
	References.....	304
<b>44</b>	<b>Orthotopic Neobladders vs. Ileal Conduits .....</b>	<b>305</b>
	References.....	306
<b>45</b>	<b>The Role of Enhanced Recovery in Robotic Cystectomy .....</b>	<b>307</b>
	References.....	308
<b>46</b>	<b>MIBC: Quality of Life with Urinary Diversion .....</b>	<b>309</b>
	References.....	311
<b>47</b>	<b>MIBC: Orthotopic vs Ileal Conduit, Which Is Better?.....</b>	<b>313</b>
	References.....	314
<b>48</b>	<b>MIBC: A Systematic Review on Orthotopic Neobladder vs. Ileal Conduit, Which Is Better? .....</b>	<b>317</b>
48.1	Incidence of Ileal Conduit vs. Orthotopic .....	318
48.2	Health Related Quality of Life.....	319
48.3	Morbidity and Mortality .....	320
48.4	AKI .....	320
48.5	Modified S Pouch Outcomes .....	321
48.6	Conversion Factors.....	321
48.7	Factors Influencing Selection of Urinary Diversion .....	322
48.8	Types of Diversion Outcomes .....	322
48.9	Systematic Reviews Relating to Urinary Diversion.....	322
	References.....	323
<b>49</b>	<b>Urinary Diversion Ileal Conduit vs. Studer vs. Catherisable Stoma .....</b>	<b>325</b>
49.1	Research Methods .....	325
49.2	T-Pouch Neobladder vs. Studer Pouch .....	327
49.3	Studer Pouch vs. I Pouch.....	327
49.4	The Studer Neobladder .....	328
49.5	Ileal Conduit vs. Neobladder .....	329
	References.....	329

<b>50</b>	<b>Robotic Cystectomy and Intracorporeal Stoma Formation: Robotic Management of Ureteric Strictures</b>	331
	References	332
<b>51</b>	<b>Management of Ureteric Stricture Disease Post Urinary Diversion in Bladder Cancer</b>	333
51.1	Systematic Review Results	335
51.1.1	Ureteric Stricture Rates Post Radical Cystectomy: Ileal Conduit vs. Orthotopic Neobladder	335
51.1.2	Rates of Ureteric Strictures: Open vs. Robotic Radical Cystectomy	335
51.1.3	New Techniques in Management of Ureteric Strictures	335
51.1.4	Ureteric Stricture Rate: Wallace vs. Bricker Anastomosis	336
51.1.5	Continuous vs. Interrupted Suture Impact on Ureteric Stricture Rate	337
51.1.6	Use of Ureteric Stents and Impact on Ureteric Stricture Rates	337
51.1.7	Impact of Prior Pelvic Irradiation On Ureteric Strictures	337
51.1.8	Development of Malignant Ureteric Strictures vs. Benign Strictures	338
51.1.9	Risk Factors for Development of Ureteric Strictures	338
51.1.10	Endoureterotomy vs. Open Surgical Revision for Ureteric Strictures	338
51.1.11	Risk of Ureteric Obstruction with Antireflux Techniques in Orthotopic Neobladders	339
51.1.12	Balloon Dilation in Ureterointestinal Anastomotic Stricture	340
	References	340
<b>52</b>	<b>Neoadjuvant Chemotherapy vs. Radical Cystectomy in Muscle Invasive Bladder Cancer</b>	343
52.1	Systematic Review Results	345
52.1.1	Neoadjuvant Chemotherapy vs. Radical Cystectomy Alone in Muscle Invasive Bladder Cancer	345
52.1.2	MVAC in Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer	345
52.1.3	MVAC vs. Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy	345
52.1.4	Impact of Cisplatin Neoadjuvant Chemotherapy on Muscle Invasive Bladder Cancer Outcomes	346
52.1.5	Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer	347

52.1.6	Gemcitabine Plus Carboplatin as Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer . . . . .	347
52.1.7	Predictors of Response in Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. . . . .	347
52.1.8	Gemcitabine, Cisplatin and Lapatinib as Neoadjuvant Chemotherapy. . . . .	349
52.1.9	Erlotinib as Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer. . . . .	349
52.1.10	Imaging to Assess Response of Muscle Invasive Bladder Cancer to Neoadjuvant Chemotherapy . . . . .	349
52.1.11	Complications from Neoadjuvant Chemotherapy . . . . .	350
52.1.12	Survival Outcomes in Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer . . . . .	351
52.1.13	Pathological Impact of Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer . . . . .	352
52.1.14	Impact of Suboptimal Neoadjuvant Chemotherapy Dosing on Outcomes in Muscle Invasive Bladder Cancer .	353
52.1.15	Neoadjuvant Chemotherapy in Radical Cystectomy vs. Radiotherapy. . . . .	353
52.1.16	Neoadjuvant Chemotherapy in a Salvage Cystectomy Setting. . . . .	354
52.1.17	Neoadjuvant Chemotherapy vs. Active Surveillance in Muscle Invasive Bladder Cancer . . . . .	354
52.1.18	Systematic Reviews Relating to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer . . . . .	354
	References. . . . .	355
<b>53</b>	<b>Radical Cystectomy and Renal Transplant . . . . .</b>	<b>359</b>
53.1	Research Methods . . . . .	359
53.2	Risk of Bladder Cancer in Renal Transplant Patients . . . . .	361
53.3	Risk and Safety of Radical Cystectomy in the Renal Transplant Patient. . . . .	361
53.4	Risk According to Type of Urinary Diversion. . . . .	361
53.5	Difficulties Encountered in Renal Transplant Patients . . . . .	362
53.6	A New Technique of Robotic Cystectomy for Renal Transplant Patients. . . . .	362
53.7	Surgical Technique in Renal Transplant Patients. . . . .	363
53.8	BCG vs. MMC in Bladder Cancer. . . . .	363
53.9	Histological Variants in the Renal Transplant Patient . . . . .	364
53.10	Presentation and Management of Bladder Cancer in the Renal Transplant Population . . . . .	364
53.11	Orthotopic Neobladders in the Renal Transplant Population . . . . .	365
53.12	Transplant Post Cystectomy and Urinary Diversion . . . . .	366
53.13	Post-operative Complications Post Radical Cystectomy. . . . .	366
53.14	Impact of CKD on Oncological Outcomes in MIBC. . . . .	366

53.15	Reviews Related to Systematic Review . . . . .	367
	References. . . . .	367
<b>54</b>	<b>Radical Cystectomy and Acute Renal Failure . . . . .</b>	<b>369</b>
54.1	AKI Post Major Surgery . . . . .	370
54.2	Risk Factors for AKI After Radical Cystectomy . . . . .	371
54.3	Impact of AKI Post Radical Cystectomy on CKD. . . . .	371
54.4	Radical Cystectomy with ARF Caused by Rhabdomyolysis. . . . .	372
54.5	Radical Cystectomy, AKI and Association with Uric Acid . . . . .	372
54.6	Radical Cystectomy: Ileal Conduit vs. Neobladder and AKI . . . . .	373
54.7	Use of Noradrenaline and Risk of Acute Renal Failure in Radical Cystectomy . . . . .	373
54.8	Radical Cystectomy, Neoadjuvant Chemotherapy and AKI . . . . .	374
<b>55</b>	<b>A Systematic Review on Bladder Cancer, Radical Cystectomy and Complications . . . . .</b>	<b>375</b>
55.1	Research Methods . . . . .	375
55.2	Impact of Type of Urinary Diversion on Complications . . . . .	377
55.3	Perioperative Complications for Robotic Radical Cystectomy and Intracorporeal Urinary Diversion . . . . .	377
55.4	Ileal Conduit vs. Orthotopic Neobladder Complication Rate . . . . .	378
55.5	Complications in Ileal Conduit Diversion . . . . .	379
55.6	Risk Factors for Complications Post Radical Cystectomy for Bladder Cancer. . . . .	379
55.7	Complication by Urinary Diversion Type . . . . .	380
55.8	Preoperative Anaemia and Impact on Post-operative Complications in Radical Cystectomy. . . . .	381
55.9	Complications Post Radical Cystectomy Using a Standardised Reporting System. . . . .	381
55.10	Complications Post Orthotopic Neobladders. . . . .	382
55.11	Complications Post Laparoscopic Radical Cystectomy . . . . .	383
55.12	Post-operative Complications of Radical Cystectomy in the Elderly . . . . .	383
55.13	Complications of Radical Cystectomy Post Prior Radiotherapy . . . . .	384
55.14	Impact of Metabolic Syndrome on Radical Cystectomy . . . . .	385
55.15	Mortality Rate and Urinary Diversion . . . . .	385
	References. . . . .	386
 <b>Part VIII Patient Fitness, CPEX Testing and Enhanced Recovery</b>		
<b>56</b>	<b>Physical Pre-habilitation Prior to Radical Cystectomy. . . . .</b>	<b>391</b>
	References. . . . .	392
<b>57</b>	<b>Exercise Therapy Pre-surgery . . . . .</b>	<b>393</b>
	Reference . . . . .	393

<b>58</b>	<b>Patient Fitness for Surgery</b> . . . . .	395
	References. . . . .	396
<b>59</b>	<b>Systematic Review on Enhanced Recovery and Radical Cystectomy</b> . . . . .	397
59.1	Research Methods . . . . .	397
59.2	ERAS vs. Standard Care Post Radical Cystectomy. . . . .	399
59.3	Adherence to ERAS Protocols. . . . .	399
59.4	Readmission Rates for ERAS . . . . .	399
59.5	Surgical Approach and the Impact of ERUS . . . . .	400
59.6	Impact of ERAS on Post-operative Recovery . . . . .	400
59.7	Patient Nonmodifiable Factors Predictive of ERAS Outcomes . . . . .	401
59.8	Impact of ERAS on Post-operative Complications . . . . .	401
59.9	Impact of ERAS on Hospital Stay . . . . .	402
59.10	Impact of Type of Fluid on ERAS . . . . .	402
59.11	Impact of Multidisciplinary Care on ERAS Outcomes . . . . .	403
59.12	Impact of PROMS on ERAS . . . . .	403
59.13	Impact of ERAS on Lymphadenectomy . . . . .	403
59.14	Pain Relief and ERAS After Radical Cystectomy . . . . .	404
59.15	Impact of ERAS on Intracorporeal Urinary Diversion . . . . .	404
59.16	Prognostic Factors for ITU Admission in ERAS. . . . .	404
59.17	Grey Matter: ERAS vs. Standard Care for Radical Cystectomy . . . . .	405
	References. . . . .	405
<b>60</b>	<b>Cardio-Pulmonary Exercise Testing and Major Urological Surgery: Risk Stratification and Preoperative Assessment</b> . . . . .	407
60.1	Cardiopulmonary Exercise Testing . . . . .	407
60.2	Other Methods of Assessment . . . . .	408
60.3	Search Strategy . . . . .	408
60.4	Systematic Review Results . . . . .	409
60.4.1	CPEX and Major Surgery: The Research So Far . . . . .	409
60.4.2	Future Research: Evaluation of CPEX. . . . .	410
	References. . . . .	410
<b>61</b>	<b>Robotic Radical Cystectomy and Enhanced Recovery: An Evolving Care Pathway</b> . . . . .	413
	References. . . . .	414
<b>62</b>	<b>Robotic Radical Cystectomy and Intracorporeal Stoma Formation: A New Technology to Guide Resection</b> . . . . .	417
	References. . . . .	418
<b>63</b>	<b>A Systematic Review on Obesity in Bladder Cancer</b> . . . . .	419
63.1	Systematic Review Results on Obesity in Bladder Cancer . . . . .	420
63.1.1	Impact of BMI on MIBC and Radical Cystectomy Outcomes . . . . .	420
63.1.2	Impact of BMI on Mortality After Radical Cystectomy . . . . .	421

63.1.3	Impact of BMI on Recurrence and Progression of Bladder Cancer: High Grade None Muscle Invasive Disease . . . . .	422
63.1.4	BMI and Risk of Recurrence in NMI Bladder Cancer . . . . .	422
63.1.5	Obesity and Risk of Bladder Cancer . . . . .	423
63.1.6	BMI and Prognosis in MIBC . . . . .	424
63.1.7	Reviews on BMI and Bladder Cancer . . . . .	424
	References . . . . .	425

## **Part IX New Techniques in Management of Muscle Invasive Bladder Cancer**

<b>64</b>	<b>A Systematic Review on Immunotherapy in Locally Advanced and Metastatic Bladder Cancer . . . . .</b>	<b>429</b>
64.1	Systematic Review Results . . . . .	431
64.1.1	Pembrolizumab and Radiotherapy in Bladder Cancer . . . . .	431
64.1.2	Atezolizumab in Locally Advanced or Metastatic Urothelial Carcinoma . . . . .	431
64.1.3	Adjuvant Bestatin Immunotherapy and Radical Radiotherapy in Bladder Cancer . . . . .	431
64.1.4	Predictors of Response to Immunotherapy . . . . .	432
64.1.5	Markers of Response to Immunotherapy . . . . .	432
64.1.6	A Normogram Predicting Survival from Immunotherapy in Locally Advanced and Metastatic Bladder Cancer . . . . .	432
64.1.7	Infusion of Autologous T Helper Cells in Metastatic Bladder Cancer . . . . .	433
64.1.8	Consensus Guidelines on Immunotherapy in Locally Advanced and Metastatic Bladder Cancer . . . . .	433
	References . . . . .	433
<b>65</b>	<b>The Role of Immune Checkpoint Inhibitors in Bladder Cancer . . . . .</b>	<b>435</b>
65.1	Systematic Review Results . . . . .	437
65.1.1	Pd-L1 Expression in Bladder Cancer . . . . .	437
65.1.2	Anti-PD-L1 and Radiotherapy . . . . .	439
65.1.3	Immune Checkpoint Inhibition in Variant Histology in Bladder Cancer . . . . .	439
65.1.4	Ramucirumab and Docetaxel vs. Placebo in Bladder Cancer . . . . .	440
65.1.5	T-Cell Immunoglobulin Mucin-3 Expression in Bladder Cancer . . . . .	441
65.1.6	Inhibition of G9a/DNMT and Immune-Mediated Bladder Cancer Regression . . . . .	441
65.1.7	Inhibition of PI3K Pathway Increases Immune Infiltrate in Muscle-Invasive Bladder Cancer . . . . .	441
65.1.8	Neoantigen-Reactive Tumour-Infiltrating Lymphocytes in Bladder Cancer . . . . .	442



65.1.9	Response Rate to Chemotherapy after Immune Checkpoint Inhibition in Metastatic Urothelial Cancer . . . . .	442
	References . . . . .	442
<b>66</b>	<b>The Role of Chemotherapy in Locally Advanced and Metastatic Bladder Cancer . . . . .</b>	<b>445</b>
66.1	Systematic Review Results . . . . .	447
66.1.1	Cis-Diamminedichloroplatinum in Locally Advanced and Metastatic Bladder Cancer . . . . .	447
66.1.2	Gemcitabine in Locally Advanced and Metastatic Bladder Cancer . . . . .	447
66.1.3	Gemcitabine and Cisplatin in Locally Advanced and Metastatic Bladder Cancer . . . . .	447
66.1.4	Neoadjuvant Gemcitabine and Cisplatin in Locally Advanced and Metastatic Bladder Cancer . . . . .	448
66.1.5	Gemcitabine and Cisplatin vs. Carboplatin and Gemcitabine in Locally Advanced and Metastatic Bladder Cancer . . . . .	448
66.1.6	Paclitaxel, Cisplatin and Gemcitabine vs. Gemcitabine and Cisplatin . . . . .	448
66.1.7	Gemcitabine and Irinotecan in Locally Advanced and Metastatic Bladder Cancer . . . . .	449
66.1.8	Carboplatin Based Chemotherapy for Locally Advanced and Metastatic Bladder Cancer . . . . .	449
66.1.9	Gemcitabine vs. Oxaliplatin for Locally Advanced and Metastatic Bladder Cancer . . . . .	450
66.1.10	Paclitaxel in Locally Advanced and Metastatic Bladder Cancer . . . . .	450
66.1.11	Neoadjuvant Cisplatin, Methotrexate and Vinblastine in Locally Advanced and Metastatic Bladder Cancer . . . . .	450
66.1.12	Larotaxel and Cisplatin vs. Gemcitabine and Cisplatin for Locally Advanced or Metastatic Bladder Cancer . . . . .	451
66.1.13	Mocetinostat in Locally Advanced and Metastatic Bladder Cancer . . . . .	451
66.1.14	Gemcitabine and Cisplatin vs. Methotrexate, Vinblastine, Doxorubicin and Cisplatin for Locally Advanced and Muscle Invasive Bladder Cancer . . . . .	452
66.1.15	Gemcitabine, Cisplatin and Sorafenib vs. Chemotherapy Alone in Locally Advanced and Metastatic Bladder Cancer . . . . .	453
66.1.16	Adjuvant Gemcitabine and Cisplatin in Locally Advanced Bladder Cancer . . . . .	454
66.1.17	Gemcitabine and Cisplatin in Renal Dysfunction for Locally Advanced and Metastatic Bladder Cancer . . . . .	454

66.1.18	Paclitaxel and Gemcitabine in Locally Advanced and Metastatic Bladder Cancer . . . . .	454
66.1.19	Paclitaxel, Gemcitabine and Cisplatin in Locally Advanced and Metastatic Bladder Cancer . . . . .	454
66.1.20	Paclitaxel, Gemcitabine and Carboplatin in Locally Advanced and Metastatic Bladder Cancer . . . . .	455
66.1.21	Paclitaxel in Platin Refractory Locally Advanced and Metastatic Bladder Cancer. . . . .	455
66.1.22	Docetaxel in Locally Advanced and Metastatic Bladder Cancer. . . . .	456
66.1.23	Docetaxel and Gemcitabine in Locally Advanced and Metastatic Bladder Cancer. . . . .	456
66.1.24	Cabizataxel vs. Vinflunine in Locally Advanced and Metastatic Bladder Cancer . . . . .	457
66.1.25	Cisplatin, Epirubicin, Methotrexate in Locally Advanced and Metastatic Bladder Cancer . . . . .	457
66.1.26	Methotrexate, Carboplatin, Mitoxantrone and Vincristine in Locally Advanced and Metastatic Bladder Cancer. . . . .	458
66.1.27	Methotrexate, Paclitaxel, Epirubicin and Carboplatin in Advanced Bladder Cancer . . . . .	458
66.1.28	Methotrexate, Carboplatin and Vinblastine in Locally Advanced and Metastatic Bladder Cancer . . . .	458
66.1.29	Methotrexate, Carboplatin, Vinblastine and Epirubicin in Locally Advanced and Metastatic Bladder Cancer. . . . .	459
66.1.30	Gemcitabine, Cisplatin and Docetaxel in Locally Advanced and Metastatic Bladder Cancer. . . . .	459
66.1.31	Everolimus in Locally Advanced and Metastatic Bladder Cancer. . . . .	460
66.1.32	Doxorubicin and Gemcitabine Followed by Isofosfamide, Paclitaxel, and Cisplatin in Locally Advanced and Metastatic Bladder Cancer . . . . .	460
66.1.33	Pemetrexed and Gemcitabine in Locally Advanced and Metastatic Bladder Cancer. . . . .	461
66.1.34	Paclitaxel and Gemcitabine in Locally Advanced and Metastatic Bladder Cancer. . . . .	461
66.1.35	Cisplatin, Epirubicin and Docetaxel in Locally Advanced and Metastatic Bladder Cancer . . . . .	461
66.1.36	Vinflunine in Locally Advanced and Metastatic Bladder Cancer. . . . .	462
66.1.37	Doxorubicin in Locally Advanced and Metastatic Bladder Cancer. . . . .	462
	References. . . . .	463

<b>67</b>	<b>Chemo-radiation in Muscle Invasive Bladder Cancer</b>	467
67.1	Systematic Review Methods	467
67.2	Systematic Review Results	469
67.2.1	Radical Cystectomy vs. Chemoradiation in Muscle Invasive Bladder Cancer	469
67.2.2	Predictors of Response to Chemoradiation in Bladder Preservation Therapy	471
67.2.3	Biochemical Markers of Response to Chemoradiation Therapy in Muscle Invasive Bladder Cancer	472
67.2.4	Alternative Regimes in Chemoradiation for Muscle Invasive Bladder Cancer	476
67.2.5	Outcomes from Chemoradiation in Muscle Invasive Bladder Cancer	478
67.2.6	Low Dose Chemoradiotherapy Outcomes in Muscle Invasive Bladder Cancer	481
67.2.7	Chemotherapy vs. Chemoradiotherapy Outcomes in Muscle Invasive Bladder Cancer	483
67.2.8	The Role of Neoadjuvant Chemotherapy Pre Chemoradiation	483
67.2.9	Neoadjuvant Chemotherapy vs. Concomitant Chemoradiation for Muscle Invasive Bladder Cancer	484
67.2.10	Chemoradiation in the Elderly or Unfit with Muscle Invasive Bladder Cancer	484
67.2.11	Female Outcomes with Chemoradiotherapy in Muscle Invasive Bladder Cancer	486
67.2.12	Patient Reported Outcome Measures in Chemoradiation Therapy	486
67.2.13	Adjuvant Chemotherapy vs. Chemoradiotherapy for Muscle Invasive Bladder Cancer	487
67.2.14	Chemoradiation in Advanced Bladder Cancer	487
67.2.15	Side Effects of Chemoradiotherapy in Muscle Invasive Bladder Cancer	487
67.2.16	Chemoradiation in Whole Bladder vs. Partial Bladder Treatment	488
67.2.17	Mortality Outcomes in Chemoradiotherapy for Muscle Invasive Bladder Cancer	488
67.2.18	International Reviews and Guidelines on Chemoradiation in Muscle Invasive Bladder Cancer	489
	References	490
<b>68</b>	<b>Trials in Localized Bladder Cancer</b>	495
68.1	Systematic Review Results	496
68.1.1	Bladder Preservation Therapy	496
68.1.2	Pre-operative Fitness	497
68.1.3	Partial Cystectomy	498

68.1.4	Open vs. Robotic Radical Cystectomy . . . . .	498
68.1.5	Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer . . . . .	500
68.1.6	Extended vs. Limited Lymph Node Dissection in Radical Cystectomy . . . . .	501
68.1.7	Sentinel Node Detection in Muscle Invasive Bladder Cancer. . . . .	501
68.1.8	Urinary Diversion Post Radical Cystectomy . . . . .	501
68.1.9	ERAS in Radical Cystectomy . . . . .	502
68.1.10	Radiotherapy in Muscle Invasive Bladder Cancer . . . . .	502
68.1.11	Chemoradiotherapy in Muscle Invasive Bladder Cancer. . . . .	502
68.1.12	Brachytherapy in Muscle Invasive Bladder Cancer . . . . .	503
	References. . . . .	503
<b>69</b>	<b>Trials in Locally Advanced and Metastatic Bladder Cancer . . . . .</b>	<b>507</b>
69.1	Systematic Review Results . . . . .	509
69.1.1	Adjuvant Chemoradiation vs. Chemotherapy Alone in Locally Advanced Bladder Cancer. . . . .	509
69.1.2	Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer. . . . .	509
69.1.3	Chemotherapy in Locally Advanced and Metastatic Bladder Cancer. . . . .	509
69.1.4	Immunotherapy in Locally Advanced and Metastatic Bladder Cancer. . . . .	513
69.1.5	Immunotherapy and Radiotherapy in Metastatic Bladder Cancer. . . . .	515
69.1.6	Chemoradiotherapy in the Elderly . . . . .	515
	References. . . . .	515
 <b>Part X Salvage Therapy</b>		
<b>70</b>	<b>A Systematic Review on Salvage Cystectomy. . . . .</b>	<b>521</b>
70.1	Research Methods . . . . .	521
70.2	Is Salvage Cystectomy Required? . . . . .	523
70.3	Survival Outcomes in Salvage Cystectomy . . . . .	523
70.4	Salvage Cystectomy After EBRT. . . . .	524
70.5	Prognostic Factors in Salvage Cystectomy . . . . .	525
70.6	Post Operative Complications for Salvage Cystectomy . . . . .	526
70.7	Salvage Cystectomy and Orthotopic Neobladder . . . . .	527
	References. . . . .	527
 <b>Part XI Bladder Cancer Survivorship</b>		
<b>71</b>	<b>Bladder Cancer Survivorship . . . . .</b>	<b>531</b>
71.1	Systematic Review. . . . .	533

71.1.1	Survivorship Differences in Demographic Factors . . . . .	533
71.1.2	Health Related Quality of Life . . . . .	533
71.1.3	Unmet Informational Needs in Bladder Cancer Survivorship . . . . .	534
71.1.4	Exercise Programming and Counselling in Bladder Cancer Survivorship . . . . .	534
71.1.5	Health Behaviours in Bladder Cancer Survivorship. . . . .	534
71.1.6	Survivorship Care Plans . . . . .	535
71.1.7	Physical Prehabilitation Prior to Cystectomy . . . . .	535
	References. . . . .	535
<b>72</b>	<b>Support for Partners in Bladder Cancer . . . . .</b>	<b>537</b>
	References. . . . .	540
<b>73</b>	<b>Muscle Invasive Bladder Cancer: What is the Impact of Radical Cystectomy on Patient Reported Outcome Measures? . . . . .</b>	<b>541</b>
73.1	Definition of Bladder Cancer Survivorship . . . . .	541
73.2	Bladder Cancer Survivorship and Patient Reported Outcome Measures: Code 1 Erectile Dysfunction . . . . .	541
73.3	Bladder Cancer Survivorship and Patient Reported Outcome Measures: Code 2 Age Related disease . . . . .	542
73.4	Bladder Cancer Survivorship and Patient Reported Outcome Measures: Code 3 Side Effects Post Operatively. . . . .	543
73.5	Bladder Cancer Survivorship and Patient Reported Outcome Measures: Code 4 Psychological Impact. . . . .	544
73.6	Bladder Cancer Survivorship and Patient Reported Outcome Measures: Code 5 Impact of Operation on General Health . . . . .	544
	References. . . . .	545
<b>74</b>	<b>Survivorship Issues in Muscle Invasive Bladder Cancer . . . . .</b>	<b>547</b>
	References. . . . .	549
<b>75</b>	<b>Muscle Invasive Bladder Cancer and Health Related Quality of Life . . . . .</b>	<b>551</b>
	References. . . . .	552
<b>76</b>	<b>Body Image in Bladder Cancer . . . . .</b>	<b>555</b>
	References. . . . .	557
<b>77</b>	<b>Psychological Impact in Bladder Cancer . . . . .</b>	<b>559</b>
77.1	Systematic Review Results . . . . .	561
77.1.1	Psychological Impairment in Patients Referred for Bladder Cancer Investigations . . . . .	561
77.1.2	Psychological Distress and Radical Cystectomy . . . . .	561
77.1.3	Psychological Distress in Smokers with Bladder Cancer. . . . .	562
77.1.4	Psychological Impact of Type of Urinary Diversion . . . . .	562

77.1.5	Quality of Life During Chemotherapy or Immunotherapy in Bladder Cancer. . . . .	563
77.1.6	Psychological Issues in Metastatic Bladder Cancer. . . . .	563
	References. . . . .	564
<b>Part XII Palliative Therapy in Muscle Invasive Bladder Cancer</b>		
<b>78</b>	<b>The Role of Palliative Cystectomy in Bladder Cancer . . . . .</b>	<b>567</b>
78.1	Research Methods . . . . .	567
78.2	Systematic Review Results . . . . .	569
78.2.1	Lymph Node Positive Bladder Cancer and Outcomes with Cystectomy . . . . .	569
78.2.2	Outcomes from Palliative Cystectomy . . . . .	570
78.2.3	Outcomes from Palliative Robotic Cystectomy . . . . .	570
78.2.4	Systematic Reviews Relating to Palliative Cystectomy . . . . .	571
	References. . . . .	571
<b>79</b>	<b>Palliative Care in Bladder Cancer. . . . .</b>	<b>573</b>
79.1	Systematic Review Results . . . . .	575
79.1.1	Surgery in Palliation . . . . .	575
79.1.2	Patient Selection in Palliative Radiotherapy. . . . .	575
79.1.3	Palliative Chemotherapy in Muscle Invasive Bladder Cancer. . . . .	576
	References. . . . .	577
	<b>Index . . . . .</b>	<b>579</b>